AMENDMENTS TO THE CLAIMS

Cancel Claims 16 to 19.

DETAILED LISTING OF ALL CLAIMS

1. (Original): A compound of the formula:



(I),

or a pharmaceutically-acceptable salt thereof, wherein

X is NR_1, CR_1, or S;

Y_1 and Y_2 are nitrogen or carbon, provided that

a) when X is CR_1, at least one of Y_1 and Y_2 is nitrogen, and b) when one of Y_1 and Y_2 is carbon, the other of Y_1 and Y_2 is nitrogen and/or X is NR_1 or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;

R_1 is hydrogen, halogen, alkyl, substituted alkyl, cyano, OR_5, NR_5R_6, $C(=O)R_5$, CO_2R_5, or aryl;

R_2 is alkyl, substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl;

R_3 and R_4 are independently selected from halogen, alkyl, substituted alkyl, nitro, cyano, OR_7, NR_7R_8, $C(=O)R_7$, CO_2R_7, SR_7, $C(=O)NR_7R_8$, $NR_7C(=O)R_8$, $NR_7C(=O)OR_8$, $S(O)_qR_7$, $NR_7SO_2R_8$, and $SO_2NR_7R_8$;

R_5, R_6, R_7, and R_8 are independently selected from hydrogen, alkyl, substituted alkyl, and phenyl, or when attached to the same nitrogen atom (as in NR_5R_6 or NR_7R_8) may join together to form a heterocycle or heteroaryl; and

m, *n* and *q* are independently 0, 1, or 2.

2. (Original): The compound of claim 1, or a pharmaceutically-acceptable salt thereof, in which X is NR_1 or CR_1, and R_1 is hydrogen, lower alkyl, or trifluoromethyl.

3. (Original): The compound of claim 1, or a pharmaceutically-acceptable salt thereof, in which X, Y_1 and Y_2 are selected so that ring A defines one of:



4. (Original): The compound of claim 1 or a pharmaceutically-acceptable salt thereof, in which:

R_2 is C_{1-4}alkyl optionally substituted with OR_9 or $NR_{10}R_{11}$;

R_9 is hydrogen or lower alkyl; and

R_{10} and R_{11} are (i) independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}substituted alkyl, and $-(C=O)C_{1-2}$alkyl, or alternatively (ii) together form a five to six membered heterocycle or heteroaryl.

5. (Original): The compound of claim 1, or a pharmaceutically-acceptable salt thereof, in which R_2 is C_{1-2} alkyl optionally substituted with one of:

OH, NH_2, $NH(C_{1-2}alkyl)$, $N(C_{1-2}alkyl)_2$, $NH(C_{1-2}substituted\ alkyl)$, $N(C_{1-2}substituted\ alkyl)_2$, $NH(C=O)C_{1-2}$alkyl, or piperidinyl.

6. (Original): The compound of claim 1 or a pharmaceutically-acceptable salt thereof, in which R_2 is aryl having zero to three substituents selected from halogen, lower alkyl, trifluoromethyl, alkoxy, and nitro.

7. (Original): The compound of claim 1 or a pharmaceutically-acceptable salt thereof, in which

X, Y_1 and Y_2 are selected so that ring A defines one of pyrazolyl, imidazolyl, or thiazolyl;

R_1 is hydrogen, methyl, ethyl, or trifluoromethyl; and

R_2 is C_{1-2}alkyl optionally substituted with one of OH, NH_2, $NH(C_{1-2}alkyl)$, $N(C_{1-2}alkyl)_2$, $NH(C=O)C_{1-2}$alkyl, or a five to six membered heterocycle.

8. (Original): The compound of claim 1, or a pharmaceutically-acceptable salt thereof, in which R_3 and R_4 are selected from halogen, alkyl, substituted alkyl, nitro, cyano, OR_7, NR_7R_8, $C(=O)R_7$, CO_2R_7, SR_7, $C(=O)NR_7R_8$, $NR_7C(=O)R_8$, $NR_7C(=O)OR_8$, $S(O)_qR_7$, $NR_7SO_2R_8$, and $SO_2NR_7R_8$;

R_7 and R_8 are independently selected from hydrogen and alkyl; and

m and *n* are independently 0, 1, or 2, provided that *m* and *n* are not both 0.

9. (Original): The compound of claim 1, or a pharmaceutically-acceptable salt thereof, in which *m* and *n* are both 0.

10. (Original): A compound having the formula,



or a pharmaceutically-acceptable salt thereof, wherein

X is NR_1, CR_1, or S;

Y_1 and Y_2 are nitrogen or carbon, provided that:

a) when X is CR_1, at least one of Y_1 and Y_2 is nitrogen, and b) when one of Y_1 and Y_2 is carbon, the other of Y_1 and Y_2 is nitrogen and/or X is NR_1 or S, so that ring A defines a five-membered heteroaryl ring having at least two heteroatoms;

R_1 is hydrogen, halogen, lower alkyl, or trifluoromethyl;

R_2 is C_{1-4} alkyl optionally substituted with a group selected from hydroxy, alkoxy, NH_2, NH(alkyl), $N(alkyl)_2$, NH(substituted alkyl), $N(substituted\ alkyl)_2$, and NH(C=O)alkyl, and heterocycle;

R_3 and R_4 are independently halogen, lower alkyl, substituted lower alkyl, nitro, cyano, alkoxy, amino, $-CO_2H$, -C(=O)H, or alkylthio; and

m and *n* are independently 0, 1, or 2.

11. (Original): The compound of claim 10, or a pharmaceutically-acceptable salt thereof, in which X, Y_1 and Y_2 are selected so that ring A defines one of:



12. (Original): The compound of claim 11, or a pharmaceutically-acceptable salt thereof, in which:

R_2 is C_{1-2} alkyl optionally substituted with a group selected from OH, NH_2, $NH(C_{1-2}alkyl)$, $N(C_{1-2}alkyl)_2$, $NH(C_{1-2}substituted\ alkyl)$, $N(C_{1-2}substituted\ alkyl)_2$, and piperidinyl.

13. (Original): The compound of claim 1, selected from (i) benzo[g]-4-(2-N-methylaminoethylamino)-1-methylimidazo[1,2-a]quinoxaline; benzo[g]-4-methylamino-1-methylimidazo[1,2-a]quinoxaline; benzo[g]-4-(2-N-methylaminoethylamino)-1-methylpyrazolo[1,2-a]quinazoline; benzo[g]-4-methylamino-1-methylpyrazolo[1,2-a]quinozoaline; 1-methyl-4-methylaminobenzo(g)-imidazo(4,5-c)quinoline; 1-methyl-4-(2-N-methylaminoethylamino)benzo(g)imidazo(4,5-c)quinoline, 1-methyl-4-methylaminobenzo(g)-thiazolo(4,5-c)quinoline; 1-methyl-4-(2-N-methylaminoethylamino)benzo(g)thiazolo(4,5-c)quinoline; 1-Methyl-4-(2-hydroxyethylamino)benzo[g]imidazo[1,2-a]quinoxaline, 1-Methyl-4-(2-piperidin-1-yl-ethylamino)benzo[g]imidazo[1,2-a]quinoxaline; and (ii) a pharmaceutically-acceptable salt thereof.

14. (Original): A pharmaceutical composition comprising (a) at least one compound according to claim 1, or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier or diluent.

15. (Original): A pharmaceutical composition comprising (a) at least one compound according to claim 10, or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier or diluent.

16. (Cancelled): A method of treating an inflammatory or immune disease or disorder comprising administering to a mammal in need thereof a therapeutically-effective amount of at least one compound according to claim 1.

17. (Cancelled): A method of treating an inflammatory or immune disease or disorder comprising administering to a mammal in need thereof a therapeutically-effective amount of at least one compound according to claim 10.

18. (Cancelled): The method of claim 16 in which the inflammatory or immune disease is selected from rheumatoid arthritis, asthma, inflammatory bowel disease, chronic obstructive pulmonary disease, and psoriasis.

19. (Cancelled): The method of claim 16 in which the inflammatory or immune disease is HIV, HSV-1, breast cancer, prostate cancer, or Hodgkin's lymphoma.